TY  - JOUR
AU  - Sarabia De Ardanaz, Luis
AU  - Andreu-Ubero, Jose M
AU  - Navidad-Fuentes, Miriam
AU  - Ferrer-González, Miguel Ángel
AU  - Ruíz Del Valle, Victor
AU  - Salcedo-Bellido, Inmaculada
AU  - Barrios-Rodríguez, Rocío
AU  - Cáliz-Cáliz, Rafael
AU  - Requena, Pilar
PY  - 2021
DO  - 10.3389/fphar.2021.620187
SN  - 1663-9812
UR  - https://hdl.handle.net/10668/26338
T2  - Frontiers in pharmacology
AB  - Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of...
LA  - en
KW  - COVID-19
KW  - immunosupression
KW  - mortality
KW  - platelet
KW  - risk factor
KW  - tocilizumab
TI  - Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment.
TY  - research article
VL  - 12
ER  -